Tekce Buket Kin, Uyeturk Ummugul, Tekce Hikmet, Uyeturk Ugur, Aktas Gulali, Akkaya Akcan
Department of Medical Biochemistry, Faculty of Medicine, Abant Izzet Baysal University, Bolu, Turkey
Department of Medical Oncology, Faculty of Medicine, Abant Izzet Baysal University, Bolu, Turkey.
Ann Clin Biochem. 2015 Jan;52(Pt 1):88-94. doi: 10.1177/0004563214528312. Epub 2014 Mar 26.
It is not possible to diagnose acute kidney injury (AKI) in early stages with traditional biomarkers. Kidney injury molecule-1 (KIM-1) is a novel biomarker promising the diagnosis of AKI in early stages. We studied whether urinary and serum KIM-1 (KIM-1 U and KIM-1 S ) concentrations were useful in predicting cisplatin-induced AKI in early stages.
We prospectively analysed 22 patients on cisplatin treatment. KIM-1 S and KIM-1 U concentrations were assessed in the samples of the patients on four different time periods (before treatment [BT], first [AT1], third [AT3] and fifth [AT5] day after treatment).
KIM-1 U concentrations on the first day after cisplatin treatment in patients with AKI were significantly increased compared to both KIM-1 U concentrations of the same patients BT (P=0.009) and to AT1-KIM-1 U concentrations of the patients without AKI (P=0.008). A receiver operating characteristic analysis revealed that AT1-KIM-1 U concentrations may predict AKI with an 87.5% sensitivity and 93.3% specificity (area under the curve=0.94). KIM-1 S concentrations were not significantly changed between BT and AT periods.
KIM-1 U concentrations may predict cisplatin-induced AKI in early stages with high sensitivity and specificity.
传统生物标志物无法在早期诊断急性肾损伤（AKI）。肾损伤分子-1（KIM-1）是一种有望在早期诊断AKI的新型生物标志物。我们研究了尿和血清KIM-1（KIM-1 U和KIM-1 S）浓度是否有助于早期预测顺铂诱导的AKI。
我们前瞻性分析了22例接受顺铂治疗的患者。在四个不同时间段（治疗前[BT]、治疗后第一天[AT1]、第三天[AT3]和第五天[AT5]）评估患者样本中的KIM-1 S和KIM-1 U浓度。
与同一患者BT时的KIM-1 U浓度（P=0.009）以及无AKI患者的AT1-KIM-1 U浓度相比，AKI患者顺铂治疗后第一天的KIM-1 U浓度显著升高（P=0.008）。受试者工作特征分析显示，AT1-KIM-1 U浓度预测AKI的敏感性为87.5%，特异性为93.3%（曲线下面积=0.94）。BT期和AT期之间KIM-1 S浓度无显著变化。
KIM-1 U浓度可在早期以高敏感性和特异性预测顺铂诱导的AKI。
